American Association for Cancer Research
Browse
15357163mct200222-sup-239823_2_supp_6374445_qcbzdx.docx (1.15 MB)

Supplementary Figure 1 from The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer–Containing Antibody–Drug Conjugates

Download (1.15 MB)
journal contribution
posted on 2023-04-03, 18:29 authored by Simon Corbett, Shiran Huang, Francesca Zammarchi, Philip W. Howard, Patrick H. van Berkel, John A. Hartley

Supplementary Figure 1. Cross-resistance of Karpas-299 and NCI-N87 resistant cell lines to common DNA interacting chemotherapeutic drugs. A. Continuous 72 h exposure in vitro growth inhibition of Karpas-299 wt, ADCr and PBDr cell lines to Cisplatin, Doxorubicin and Melphalan. B. Continuous 144 h exposure in vitro growth inhibition of NCI-N87 wt, ADCr and PBDr cell lines to Cisplatin, Doxorubicin and Melphalan. Each data point represents the average of at least 3 biological repeats with +/- SD error bars.

Funding

Cancer Research UK

History

ARTICLE ABSTRACT

Antibody–drug conjugates (ADC) containing pyrrolobenzodiazepine (PBD) dimers are being evaluated clinically in both hematologic and solid tumors. These include ADCT-301 (camidanlumab tesirine) and ADCT-402 (loncastuximab tesirine) in pivotal phase II trials that contain the payload tesirine, which releases the PBD dimer warhead SG3199. An important consideration in future clinical development is acquired resistance. The aim was to generate and characterize PBD acquired resistant cell lines in both hematologic and solid tumor settings. Human Karpas-299 (ALCL) and NCI-N87 (gastric cancer) cells were incubated with increasing IC50 doses of ADC (targeting CD25 and HER2, respectively) or SG3199 in a pulsed manner until stable acquired resistance was established. The level of resistance achieved was approximately 3,000-fold for ADCT-301 and 3-fold for SG3199 in Karpas-299, and 8-fold for ADCT-502 and 4-fold for SG3199 in NCI-N87. Cross-resistance between ADC and SG3199, and with an alternative PBD-containing ADC or PBD dimer was observed. The acquired resistant lines produced fewer DNA interstrand cross-links, indicating an upstream mechanism of resistance. Loss of antibody binding or internalization was not observed. A human drug transporter PCR Array revealed several genes upregulated in all the resistant cell lines, including ABCG2 and ABCC2, but not ABCB1(MDR1). These findings were confirmed by RT-PCR and Western blot, and inhibitors and siRNA knockdown of ABCG2 and ABCC2 recovered drug sensitivity. These data show that acquired resistance to PBD-ADCs and SG3199 can involve specific ATP-binding cassette drug transporters. This has clinical implications as potential biomarkers of resistance and for the rational design of drug combinations.